|
Cardiomegaly
|
0.500 |
Biomarker
|
phenotype |
CTD_human |
Ablation of aryl hydrocarbon receptor promotes angiotensin II-induced cardiac fibrosis through enhanced c-Jun/HIF-1α signaling.
|
31016362 |
2019 |
|
Cardiomegaly
|
0.500 |
Biomarker
|
phenotype |
CTD_human |
Irisin attenuates angiotensin II-induced cardiac fibrosis via Nrf2 mediated inhibition of ROS/ TGFβ1/Smad2/3 signaling axis.
|
30703374 |
2019 |
|
Cardiomegaly
|
0.500 |
Therapeutic
|
phenotype |
CTD_human |
Ablation of aryl hydrocarbon receptor promotes angiotensin II-induced cardiac fibrosis through enhanced c-Jun/HIF-1α signaling.
|
31016362 |
2019 |
|
Cardiomegaly
|
0.500 |
Therapeutic
|
phenotype |
CTD_human |
Irisin attenuates angiotensin II-induced cardiac fibrosis via Nrf2 mediated inhibition of ROS/ TGFβ1/Smad2/3 signaling axis.
|
30703374 |
2019 |
|
Cardiomegaly
|
0.500 |
Therapeutic
|
phenotype |
CTD_human |
Sulforaphane prevents angiotensin II-induced cardiomyopathy by activation of Nrf2 via stimulating the Akt/GSK-3ß/Fyn pathway.
|
29353218 |
2018 |
|
Cardiomegaly
|
0.500 |
Biomarker
|
phenotype |
CTD_human |
Sulforaphane prevents angiotensin II-induced cardiomyopathy by activation of Nrf2 via stimulating the Akt/GSK-3ß/Fyn pathway.
|
29353218 |
2018 |
|
Cardiomegaly
|
0.500 |
Therapeutic
|
phenotype |
CTD_human |
SIRT4 accelerates Ang II-induced pathological cardiac hypertrophy by inhibiting manganese superoxide dismutase activity.
|
27099261 |
2017 |
|
Cardiomegaly
|
0.500 |
Biomarker
|
phenotype |
CTD_human |
SIRT4 accelerates Ang II-induced pathological cardiac hypertrophy by inhibiting manganese superoxide dismutase activity.
|
27099261 |
2017 |
|
Cardiomegaly
|
0.500 |
Therapeutic
|
phenotype |
CTD_human |
Polydatin prevents angiotensin II-induced cardiac hypertrophy and myocardial superoxide generation.
|
25488910 |
2015 |
|
Cardiomegaly
|
0.500 |
Biomarker
|
phenotype |
CTD_human |
Polydatin prevents angiotensin II-induced cardiac hypertrophy and myocardial superoxide generation.
|
25488910 |
2015 |
|
Cardiomegaly
|
0.500 |
Therapeutic
|
phenotype |
CTD_human |
Roles of cGMP-dependent protein kinase I (cGKI) and PDE5 in the regulation of Ang II-induced cardiac hypertrophy and fibrosis.
|
25139994 |
2014 |
|
Cardiomegaly
|
0.500 |
Therapeutic
|
phenotype |
CTD_human |
Chronic infusion of enalaprilat into hypothalamic paraventricular nucleus attenuates angiotensin II-induced hypertension and cardiac hypertrophy by restoring neurotransmitters and cytokines.
|
24342267 |
2014 |
|
Cardiomegaly
|
0.500 |
Biomarker
|
phenotype |
RGD |
Chronic infusion of enalaprilat into hypothalamic paraventricular nucleus attenuates angiotensin II-induced hypertension and cardiac hypertrophy by restoring neurotransmitters and cytokines.
|
24342267 |
2014 |
|
Cardiomegaly
|
0.500 |
Biomarker
|
phenotype |
CTD_human |
Roles of cGMP-dependent protein kinase I (cGKI) and PDE5 in the regulation of Ang II-induced cardiac hypertrophy and fibrosis.
|
25139994 |
2014 |
|
Cardiomegaly
|
0.500 |
Biomarker
|
phenotype |
CTD_human |
Chronic infusion of enalaprilat into hypothalamic paraventricular nucleus attenuates angiotensin II-induced hypertension and cardiac hypertrophy by restoring neurotransmitters and cytokines.
|
24342267 |
2014 |
|
Cardiomegaly
|
0.500 |
Therapeutic
|
phenotype |
CTD_human |
Reduced isoproterenol-induced renin-angiotensin changes and extracellular matrix deposition in hearts of TGR(A1-7)3292 rats.
|
20409916 |
2013 |
|
Cardiomegaly
|
0.500 |
Biomarker
|
phenotype |
CTD_human |
Sirtuin 6 protects cardiomyocytes from hypertrophy in vitro via inhibition of NF-κB-dependent transcriptional activity.
|
22335191 |
2013 |
|
Cardiomegaly
|
0.500 |
Therapeutic
|
phenotype |
CTD_human |
Sirtuin 6 protects cardiomyocytes from hypertrophy in vitro via inhibition of NF-κB-dependent transcriptional activity.
|
22335191 |
2013 |
|
Cardiomegaly
|
0.500 |
Biomarker
|
phenotype |
CTD_human |
Reduced isoproterenol-induced renin-angiotensin changes and extracellular matrix deposition in hearts of TGR(A1-7)3292 rats.
|
20409916 |
2013 |
|
Cardiomegaly
|
0.500 |
Biomarker
|
phenotype |
CTD_human |
The epidermal growth factor receptor is involved in angiotensin II but not aldosterone/salt-induced cardiac remodelling.
|
22291909 |
2012 |
|
Cardiomegaly
|
0.500 |
Therapeutic
|
phenotype |
CTD_human |
The epidermal growth factor receptor is involved in angiotensin II but not aldosterone/salt-induced cardiac remodelling.
|
22291909 |
2012 |
|
Cardiomegaly
|
0.500 |
Biomarker
|
phenotype |
RGD |
Angiotensin II increases periostin expression via Ras/p38 MAPK/CREB and ERK1/2/TGF-β1 pathways in cardiac fibroblasts.
|
21367774 |
2011 |
|
Cardiomegaly
|
0.500 |
Therapeutic
|
phenotype |
CTD_human |
Levosimendan improves cardiac function and survival in rats with angiotensin II-induced hypertensive heart failure.
|
20811386 |
2010 |
|
Cardiomegaly
|
0.500 |
Therapeutic
|
phenotype |
CTD_human |
The IP3 receptor regulates cardiac hypertrophy in response to select stimuli.
|
20616315 |
2010 |
|
Cardiomegaly
|
0.500 |
Therapeutic
|
phenotype |
CTD_human |
Resveratrol induces mitochondrial biogenesis and ameliorates Ang II-induced cardiac remodeling in transgenic rats harboring human renin and angiotensinogen genes.
|
20429690 |
2010 |